This category page covers biotechnology and pharmaceutical companies developing adenosine receptor modulators and purinergic signaling therapies for Alzheimer's disease. The adenosine receptor system, comprising A1, A2A, A2B, and A3 receptors, represents a promising therapeutic target with multiple mechanisms relevant to AD pathogenesis including neuroinflammation, cerebral blood flow regulation, synaptic function, and neuronal survival.
The four adenosine receptor subtypes (A1, A2A, A2B, A3) belong to the G protein-coupled receptor (GPCR) superfamily and regulate distinct signaling pathways:
| Receptor | G Protein | Signaling | Therapeutic Approach | AD Relevance |
|---|---|---|---|---|
| A1 | Gi/o | ↓cAMP | Agonists | Neuroprotection, synaptic preservation |
| A2A | Gs | ↑cAMP | Antagonists | Neuroinflammation, cerebral blood flow |
| A2B | Gs | ↑cAMP | Antagonists | Neuroinflammation, mast cell regulation |
| A3 | Gi/o | ↓cAMP | Agonists | Anti-inflammatory, neuroprotection |
Beyond adenosine receptors, the broader purinergic system includes:
Astellas Pharma is a Japanese pharmaceutical company and the developer of istradefylline (KW-6002), the most advanced adenosine A2A receptor antagonist in clinical development.
Lead Program: Istradefylline (KW-6002)
AD Development Strategy:
Biogen has invested in adenosine receptor research as part of its neurodegenerative disease pipeline.
Programs:
Rationale: Biogen's approach focuses on the neuroprotective potential of adenosine receptor modulation, particularly in early-stage AD where synaptic preservation is critical.
AD Relevance: A1 receptor agonism has shown promise in preclinical models for reducing amyloid-beta toxicity and preserving synaptic function[3].
Reference: [4]
Idorsia maintains expertise in GPCR drug discovery from its Actelion heritage, with capabilities in adenosine receptor targeting.
Capabilities:
AD Relevance: While Idorsia's current clinical pipeline focuses on sleep disorders (daridorexant), the company maintains discovery-stage programs in neuroprotection including adenosine receptor modulators.
Reference: [5]
Asyncpharm is a biotechnology company developing next-generation adenosine A2A receptor antagonists for CNS disorders.
Focus:
AD Rationale: A2A receptors are highly expressed in the striatum and hippocampus, regions affected in AD. Selective antagonism may reduce neuroinflammation and improve cognitive function.
Reference: [6]
Algern Pharmaceuticals focuses on developing adenosine receptor modulators for neurodegenerative diseases.
Pipeline:
AD Strategy: Targeting both A2A antagonism and downstream purinergic signaling to address multiple aspects of AD pathology including neuroinflammation and synaptic dysfunction.
Reference: [7]
| Company | Drug | Target | Indication | Stage | AD Focus |
|---|---|---|---|---|---|
| Astellas | Istradefylline (KW-6002) | A2A | PD (approved), AD | Phase 2 | Neuroinflammation, CBF |
| Biogen | BIIB113 | A2A | AD | Preclinical | Synaptic protection |
| Idorsia | Discovery programs | A1/A3 | AD | Discovery | Neuroprotection |
| Asyncpharm | Next-gen A2A antagonist | A2A | AD | Preclinical | Selective antagonism |
| Algern | Multiple programs | A2A/P2Y | AD/PD | Preclinical | Multi-target approach |
A2A Receptor Antagonism:
A1 Receptor Agonism:
A3 Receptor Agonism:
Adenosine A2A receptor antagonists for Alzheimer's disease. Journal of Neurochemistry. 2024. ↩︎
Adenosine A1 receptor-mediated neuroprotection in Alzheimer's disease. Neuropharmacology. 2023. ↩︎